Inflammatory marker variations in critical COVID-19 patients treated with Tocilizumab and their correlation with clinical outcomes
Objective To analyze the changes of inflammatory markers in critical COVID-19 patients during the administration of Tocilizumab and their relationships with clinical prognosis.Methods The retrospective cohort study method was used.The study enrolled patients who were diagnosed as critical COVID-19 cases,treated with Tocilizumab and dynamic monitored inflammatory markers in Peking University First Hospital from December 2022 to February 2023.The clinical data were collected and the patients were divided into clinical deterioration group and non-clinical deterioration group according to the clinical outcomes on the 14th day.A generalized linear mixed model was used to describe the overall changes of interleukin-6(IL-6)and hypersensitive C-reactive protein(hsCRP)before and after the administration of Tocilizumab,and compare the changes of IL-6 and hsCRP in groups with different clinical outcomes.Results A total of 46 patients were enrolled in the study.After 14 days,22 cases showed clinical deterioration and 24 cases had no clinical deterioration.Generalized linear mixed model showed that IL-6 increased on the 1st day after the administration of Tocilizumab and decreased on the 3rd and 5th day.The level of hsCRP decreased continuously.The clinical deterioration group maintained higher level of IL-6 than that in the non-clinical deterioration group.On the 5th day,the changes in both groups varied,i.e.the levels of IL-6 increased in the clinical deterioration group and decreased in the non-clinical deterioration group.Conclusions The clinical prognosis of patients were poor if IL-6 level was high after admission of Tocilizumab and maintain increasing from the 5th day.
万方数据
维普
